FDA Approves Clesrovimab-cfor for Prevention of RSV in Infants
Drug Topics
JUNE 10, 2025
“RSV disease is the leading cause of infant hospitalization in the US and can lead to serious respiratory conditions like bronchiolitis and pneumonia,” Octavio Ramilo, an investigator on the CLEVER and SMART trials., The most common adverse reactions were injection-site erythema, injection-site swelling and rash.
430 
Let's personalize your content